Brazilian Journal of Pain
https://brjp.org.br/article/doi/10.5935/2595-0118.20230022-en
Brazilian Journal of Pain
Review Article

Cannabinoids for the treatment of autism and childhood epilepsy

Canabinoides no tratamento do autismo e epilepsia infantil 

Paula Maria Preto Mimura; Lisiane Seguti Ferreira; Carla Leal Pereira

Downloads: 0
Views: 134

Abstract

BACKGROUND AND OBJECTIVES: Epilepsy and autism spectrum disorder (ASD) are diseases with neuropsychiatric impairment, which, depending on their clinical presentation, can be treated with medical cannabis. The objective of this work is to present a brief review of the literature on the use of cannabinoids (CNB) in the management of ASD and epilepsy. 
CONTENTS: The elaboration of this review was made from search and selection. Searches were carried out in the following databases: LILACS, Medline via Pubmed, Scielo and Cochrane Library, published from January 2010 to December 2022. 
CONCLUSION: The use of CNB, both for epilepsy and for ASD, has been shown to be safe, however actual effectiveness has yet to be proven.

Keywords

Autism, Cannabidiol, Cannabis, Epilepsy.

Resumo

JUSTIFICATIVA E OBJETIVOS: A epilepsia e o transtorno do espectro do autismo (TEA) são doenças com comprometimento neuropsiquiátrico, os quais, dependendo da sua apresentação clínica, podem ser tratados com a cannabis medicinal. O objetivo deste estudo foi apresentar uma breve revisão da literatura sobre o uso de canabinoides (CNB) no manejo do TEA e da epilepsia. 
CONTEÚDO: A elaboração desta revisão foi feita a partir de busca e seleção. Foram realizadas buscas nas bases de dados: LILACS, Medline via Pubmed, Scielo e Cochrane Library, publicados no período de janeiro de 2010 a dezembro de 2022. 
CONCLUSÃO: O uso dos CNB, tanto para epilepsia quanto para o TEA, tem se mostrado seguro, porém a real eficácia ainda não foi comprovada.

Palavras-chave

Autismo, Canabidiol, Cannabis, Epilepsia

References

1 Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen Hauser W, Mathern G, Moshé SL, Perucca E, Wiebe S, French J. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia. 2010;51(6):1069-77. Erratum in: Epilepsia. 2010;51(9):1922.

2 Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross JH, Elger CE, Engel J Jr, Forsgren L, French JA, Glynn M, Hesdorffer DC, Lee BI, Mathern GW, Moshé SL, Perucca E, Scheffer IE, Tomson T, Watanabe M, Wiebe S. ILAE official report: a practical clinical definition of epilepsy. Epilepsia. 2014;55(4):475-82.

3 Holmes H, Sawer F, Clark M. Autism spectrum disorders and epilepsy in children: A commentary on the occurrence of autism in epilepsy; how it can present differently, and the challenges associated with diagnosis. Epilepsy Behav. 2021; 117:107813.

4 Golyala A, Kwan P. Drug development for refractory epilepsy: The past 25 years and beyond. Seizure. 2017;44:147-56.

5 McPheeters ML, Warren Z, Sathe N, Bruzek JL, Krishnaswami S, Jerome RN, Veenstra-Vanderweele J. A systematic review of medical treatments for children with autism spectrum disorders. Pediatrics. 2011;127(5):e1312-21.

6 Scheffer IE, Halford JJ, Miller I, Nabbout R, Sanchez-Carpintero R, Shiloh-Malawsky Y, Wong M, Zolnowska M, Checketts D, Dunayevich E, Devinsky O. Add-on cannabidiol in patients with Dravet syndrome: results of a long-term open-label extension trial. Epilepsia. 2021;62(10):2505-17.

7 Devinsky O, Patel AD, Thiele EA, Wong MH, Appleton R, Harden CL, Greenwood S, Morrison G, Sommerville K; GWPCARE1 Part A Study Group. Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome. Neurology. 2018;90(14):e1204-e1211.

8 Devinsky O, Cross JH, Laux L, Marsh E, Miller I, Nabbout R, Scheffer IE, Thiele EA, Wright S; Cannabidiol in Dravet syndrome study group. trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med. 2017;25;376(21):2011-20.

9 Zhang L, Wang J, Wang C. Efficacy and safety of antiseizure medication for Lennox-Gastaut syndrome: a systematic review and network meta-analysis. Dev Me Child Neurol. 2022;64(3):305-13.

10 Devinsky O, Patel AD, Cross JHl, Villanueva V, Wirrell EC, Privitera M, Greenwood SM, Roberts C, Checketts D, VanLandingham KE, Zuberi SM; GWPCARE3 Study Group. Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome. N Engl J Med. 2018;378(20):1888-97.

11 Thiele EA, Bebin EM, Filloux F, Kwan P, Loftus R, Sahebkar F, Sparagana S, Wheless J. Long-term cannabidiol treatment for seizures in patients with tuberous sclerosis complex: An open-label extension trial. Epilepsia. 2022;63(2):426-39.

12 Samanta D. A scoping review on cannabidiol therapy in tuberous sclerosis: Current evidence and perspectives for future development. Epilepsy Behav. 2022; 128:108577.

13 As informações da bula do Epidiolex podem ser acessadas no site: https://pp.jazzpharma.com/pi/epidiolex.en.USPI.pdf#page=32.

14 Bar-Lev Schleider L, Mechoulam R, Saban N, Meiri G, Novack V. Real life experience of medical cannabis treatment in autism: analysis of safety and efficacy. Sci Rep. 2019;9(1):200.

15 Aran A, Harel M, Cassuto H, Polyansky L, Schnapp A, Wattad N, Shmueli D, Golan D, Castellanos FX. Cannabinoid treatment for autism: a proof-of-concept randomized trial. Mol Autism. 2021;12(1):6.

16 As informações do FDA sobre o uso do canabidiol podem ser acessadas no site: https://www.fda.gov/news-events/fda-voices/better-data-better-understanding-use-and-safety-profile-cannabidiol-cbd-products

17 Volkow ND, Baler RD, Compton WM, Weiss SR. Adverse health effects of marijuana use. N Engl J Med. 2014;370(23):2219-27.

18 Siafis S, Çıray O, Wu H, Schneider-Thoma J, Bighelli I, Krause M, Rodolico A, Ceraso A, Deste G, Huhn M, Fraguas D, San José Cáceres A, Mavridis D, Charman T, Murphy DG, Parellada M, Arango C, Leucht S. Pharmacological and dietary-supplement treatments for autism spectrum disorder: a systematic review and network meta-analysis. Mol Autism. 2022;13(1):10.

19 Fuentes J, Hervás A, Howlin P; (ESCAP ASD Working Party). ESCAP practice guidance for autism: a summary of evidence-based recommendations for diagnosis and treatment. Eur Child Adolesc Psychiatry. 2021;30(6):961-84.
 


Submitted date:
06/22/2022

Accepted date:
03/13/2023

65553698a953952b7a114022 brjp Articles

BrJP

Share this page
Page Sections